New findings presented at the 2026 American Diabetes Association Scientific Sessions in New Orleans suggest that pharmacist continuing education programs may help reduce clinical inertia in type 2 diabetes. The findings point to a growing need for practical, pharmacist-led support when treatment goals are not being met.
Clinical inertia remains a major concern in diabetes care because many patients stay on the same treatment plan even when their blood sugar remains above target. The ADA 2026 data show that targeted education may help pharmacists identify these delays earlier and support more timely care decisions.
Why Clinical Inertia Matters In Type 2 Diabetes?
Clinical inertia happens when treatment is not started, changed, or intensified at the right time. In type 2 diabetes, this can mean a patient continues with the same medicine or dose even when their A1C level remains high.
Over time, delayed treatment changes may increase the risk of diabetes-related problems. These can include heart disease, kidney disease, nerve damage, vision issues, and poor long-term blood sugar control. This is why timely treatment review is important for both patients and care teams.
Key Findings From The Pharmacist Education Study
The ADA 2026 poster focused on a pharmacist educational outcomes study. Researchers looked at barriers that contribute to clinical inertia and measured how targeted continuing education affected pharmacist confidence and competence.
Before the education program, 650 pharmacists completed a survey. The survey asked about confidence in therapy intensification, use of diabetes guidelines, patient counseling, treatment selection, and barriers that delay treatment changes.
Insurance And Medication Access Were Major Barriers
The study found that insurance restrictions and medication access were the most common challenges reported by pharmacists. About 41% of pharmacists identified these issues as a barrier to better type 2 diabetes management.
This finding is important because many effective diabetes medicines may not be easy for patients to obtain. Prior authorizations, high copays, coverage denials, and pharmacy access issues can delay therapy even when a clinician recommends the right treatment.
Patient Adherence And Lifestyle Challenges Also Played A Role
Patient adherence and lifestyle-related challenges were another major concern. Around 37% of pharmacists reported these as significant barriers to diabetes care and treatment success.
Many patients struggle to take medicines consistently because of cost, side effects, busy schedules, limited health knowledge, or competing life priorities. These real-world issues can slow treatment progress and make it harder for patients to reach their blood sugar goals.
Treatment Sequencing Is Becoming More Complex
The ADA 2026 findings also noted that some pharmacists reported uncertainty around therapy sequencing. This means there can be confusion about which medicine should come next when a patient needs stronger treatment.
Diabetes care has expanded quickly in recent years. Providers now consider GLP-1 receptor agonists, dual incretin therapies, SGLT2 inhibitors, insulin options, cardiovascular protection, kidney protection, weight impact, safety, and affordability. This makes treatment decisions more personalized but also more complex.
Continuing Education May Improve Pharmacist Confidence
After the education program, 900 pharmacists completed post-program assessments. Investigators reported consistent improvement in pharmacist confidence and competence after the continuing education sessions.
The education focused on real patient cases, guideline-based decision-making, and practical treatment strategies. This type of learning may help pharmacists feel more prepared to recognize treatment delays and support timely therapy changes.
How Pharmacists Can Help Reduce Treatment Delays?
Pharmacists are often close to the patient’s daily medication experience. They can notice refill gaps, affordability problems, side effects, confusion about directions, and barriers that may not come up during a short clinic visit.
They may also help with prior authorizations, medication counseling, adherence checks, therapy reviews, and communication with prescribers. These steps can help reduce delays and keep patients more engaged in their diabetes care plan.
Why This Matters For Patients?
For patients, the ADA 2026 findings show that diabetes care is not only about choosing medicine. It also depends on access, education, support, follow-up, and clear communication between patients and health professionals.
A pharmacist who understands updated diabetes guidelines can help patients ask better questions, understand their medicines, and identify problems earlier. This may improve confidence and make diabetes care feel less overwhelming.
Why This Matters For Pharmacies And Health Systems?
For pharmacies and health systems, the findings support the value of pharmacist training in chronic disease management. Continuing education can help pharmacists apply guidelines in everyday practice instead of only learning theory.
This may be especially useful in ambulatory care, community pharmacy, and hospital settings where pharmacists regularly support medication access and patient education. Better training may also improve teamwork between pharmacists, physicians, nurses, and diabetes educators.
Real-World Barriers Need Real-World Solutions
The ADA 2026 study shows that clinical inertia is not caused by one single issue. It often comes from a mix of patient concerns, provider uncertainty, insurance rules, medicine costs, and system-level delays.
Because of this, solutions must also be practical. Pharmacists may need tools for treatment review, stronger communication pathways with prescribers, patient-friendly counseling methods, and updated education on newer diabetes therapies.
A Step Forward For Diabetes Care
The ADA 2026 findings suggest that pharmacist CE programs may be a useful strategy to reduce clinical inertia in type 2 diabetes. The improvement in confidence and competence shows that focused education can help pharmacists take a more active role.
While education alone cannot solve every barrier, it may support earlier action, better counseling, and stronger patient follow-up. For people living with type 2 diabetes, this could mean fewer delays and more support in reaching treatment goals.
